Overview

* Trevi Q2 adjusted EPS beats analyst expectations, net loss narrows to $12.3 mln

* Co closed $115 mln underwritten offering, cash runway expected into 2029

Outlook

* Trevi expects cash runway into 2029

* Company plans Phase 3 Haduvio trial in H1 2026

* Trevi to request FDA End-of-Phase 2 meeting in Q4 2025

Result Drivers

* PHASE 2B CORAL TRIAL - Positive topline results for Haduvio in chronic cough with IPF, achieving significant reductions in cough frequency

* CASH RUNWAY - $115 mln offering completed, extending cash runway into 2029

* R&D EXPENSES - Decrease in R&D expenses due to lower clinical development costs in Phase 2a and 2b trials

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 EPS Beat -$0.09 -$0.1

(10

Analysts

)

Q2 Net -$12.30

Income mln

Q2 Miss -$13.72 -$13.30

Income mln mln (10

from Analysts

Operatio )

ns

Q2 $13.72

Operatin mln

g

Expenses

Q2 -$12.32

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Trevi Therapeutics Inc ( TRVI ) is $22.00, about 67% above its August 6 closing price of $7.27

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)